One such example is the switchable and controllable RevCAR platform, which has been proven to be suitable for combinatorial targeting of PSCA- and PSMA-positive cancers while retaining flexibility and controllability of engineered CAR T-cells [15]. Here, FOLH1 is linked to cancer.